Neoadjuvant Pazopanib Treatment in High-Risk Soft Tissue Sarcoma: A Quantitative Dynamic (18)F-FDG PET/CT Study of the German Interdisciplinary Sarcoma Group

The outcome of high-risk soft tissue sarcoma (STS) is poor with radical surgery being the only potentially curative modality. Pazopanib is a multikinase inhibitor approved for the treatment of metastatic STS. Herein, in terms of the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS) trial, we e...

Descripción completa

Detalles Bibliográficos
Autores principales: Sachpekidis, Christos, Karampinis, Ioannis, Jakob, Jens, Kasper, Bernd, Nowak, Kai, Pilz, Lothar, Attenberger, Ulrike, Gaiser, Timo, Derigs, Hans-Günter, Schwarzbach, Matthias, Hohenberger, Peter, Dimitrakopoulou-Strauss, Antonia, Ronellenfitsch, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628287/
https://www.ncbi.nlm.nih.gov/pubmed/31181713
http://dx.doi.org/10.3390/cancers11060790

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628287/
https://www.ncbi.nlm.nih.gov/pubmed/31181713
http://dx.doi.org/10.3390/cancers11060790

Ejemplares similares